---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-23-000102"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:17:42.274855+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bankruptcy court approves Sorrento settlement; two scenarios could resolve ImmunityBio litigation

## Summary
- Bankruptcy court approved settlement on Aug 14, 2023 between ImmunityBio and Sorrento (Case No. 23-90085).
- Scenario A: If Sorrento raises funds by Aug 31, it pays judgments to NantCell and NANTibody and can proceed with litigation.
- Scenario B: If not, judgments released, Sorrento relinquishes interests in NANTibody and forfeits antibody license rights.
- As of June 30, 2023, ImmunityBio had recorded no receivables on the judgments; outcome remains uncertain.
- Settlement includes release of derivative litigation in Los Angeles Superior Court; now binding on parties.

## SEC filing metadata
- accession: 0001326110-23-000102
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000102/0001326110-23-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000102/ibrx-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-23-000102
- JSON: https://secwatch.observer/filing/0001326110-23-000102.json
- Plain text: https://secwatch.observer/filing/0001326110-23-000102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.